Vacuum-assisted Laser Ablation (VALA) for Treatment of Large Saphenous Veins
Endovenous Vacuum-assisted Laser Ablation (VALA) in the Treatment of Large Saphenous Veins (> 15 mm)
1 other identifier
interventional
184
4 countries
9
Brief Summary
Endovenous thermal ablation (EVTA), including radiofrequency ablation (RFA) and endovenous laser ablation (EVLA), is considered the main method for the treatment of symptomatic truncal vein reflux. However, there are controversial data concerning their efficacy and safety in ablating large saphenous veins because of high risk of heat-induced thrombosis (EHIT), incomplete ablation and recanalization.1-5 The use of vacuum evacuation of the remaining intraluminal blood during endovenous laser ablation allows to decrease the risk of intraoperative (carbonization and destruction of the fiber lens) and postoperative complications (EHIT, hyperpigmentation, "string" feeling) and leads to reduction of recovery because of short period of vein resorption. The aim of the study is to evaluate the safety and effectiveness of endovenous thermal ablation with or without vacuum evacuation for the treatment of incompetent large saphenous veins (\>15 mm).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2025
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 15, 2025
CompletedFirst Submitted
Initial submission to the registry
May 2, 2025
CompletedFirst Posted
Study publicly available on registry
May 14, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 15, 2026
CompletedMay 14, 2025
May 1, 2025
6 months
May 2, 2025
May 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Occlusion of the treated GSV/SSV
Obliteration of varicose vein along the treated segment of the GSV/SSV measured using ultrasound (US) examination
One day, 2 weeks, one month, 3 months and 6 months post treatment
Secondary Outcomes (7)
Pain score and use of painkillers
One day, 2 weeks, one month, 3 months and 6 months post treatment
Clinical status
2 weeks, one month, 3 months and 6 months post treatment
Severity of chronic venous diseases
2 weeks, one month, 3 months and 6 months post treatment
Health related quality of life
one month, 3 months and 6 months post treatment
Histological picture of the treated vein
2 weeks, one month, 3 months post treatment
- +2 more secondary outcomes
Study Arms (2)
Radial 2ring fiber
ACTIVE COMPARATORRefluxing GSV/SSV treated with endovenous laser ablation using ELVeS Radial 2ring fiber
Radial 2ring Pro fiber
ACTIVE COMPARATORRefluxing GSV/SSV treated with endovenous laser ablation using ELVeS Radial 2ring Pro fiber
Interventions
Great or small saphenous vein occlusion with endovenous laser ablation using ELVeS Radial 2ring fiber
Great or small saphenous vein occlusion with endovenous laser ablation using ELVeS Radial 2ring Pro fiber
Eligibility Criteria
You may qualify if:
- Age over 18 years
- Varicose veins of the lower extremities with clinical class C2-C6 with a diameter of the GSV or SSV ≥ 15 mm in a standing position
- Informed consent
You may not qualify if:
- pregnancy or lactation
- malignant neoplasms
- inability or unwillingness of any patient to wear compression stockings
- hypersensitivity to lidocaine
- concomitant diseases: diabetes mellitus, bronchial asthma, severe liver and kidney diseases, acute thrombosis and thrombophlebitis, skin and/or soft tissue infection, infectious diseases, obliterating peripheral arteriosclerosis, diabetic angiopathy, heart defects requiring surgical intervention, fever, toxic hyperthyroidism, obesity, tuberculosis, sepsis, blood cell composition disorder, all diseases requiring bed rest, heart disease with decompensation, known hereditary thrombophilia
- period after treatment for alcohol addiction
- sedentary lifestyle
- history of acute deep vein thrombosis
- history of superficial thrombophlebitis
- history of drug or other addiction
- use of oral contraceptives or other hormonal drugs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
Clinic in Uruchye
Minsk, Belarus
Merci clinic
Minsk, Belarus
SANTE clinic
Minsk, Belarus
Center Of Phlebology
Bishkek, Chuy Region, 720023, Kyrgyzstan
Laser Surgery Center
Moscow, Russia
Innovative vascular centre
Saint Petersburg, Russia
Derzhavin Tambov State University
Tambov, 392002, Russia
Clinic of Modern Phlebology "VarikozOFF"
Tashkent, Uzbekistan
Clinic of Modern Phlebology "VarikozOFF"
Tashkent, Uzbekistan
Related Publications (5)
Van der Velden SK, Lawaetz M, De Maeseneer MG, Hollestein L, Nijsten T, van den Bos RR; Members of the Predictors of Endovenous Thermal Ablation Group. Predictors of Recanalization of the Great Saphenous Vein in Randomized Controlled Trials 1 Year After Endovenous Thermal Ablation. Eur J Vasc Endovasc Surg. 2016 Aug;52(2):234-41. doi: 10.1016/j.ejvs.2016.01.021. Epub 2016 Mar 16.
PMID: 26994834BACKGROUNDSufian S, Arnez A, Labropoulos N, Lakhanpal S. Endovenous heat-induced thrombosis after ablation with 1470 nm laser: Incidence, progression, and risk factors. Phlebology. 2015 Jun;30(5):325-30. doi: 10.1177/0268355514526588. Epub 2014 Mar 7.
PMID: 24609619BACKGROUNDBontinis V, Bontinis A, Koutsoumpelis A, Potouridis A, Giannopoulos A, Rafailidis V, Chorti A, Ktenidis K. Endovenous thermal ablation in the treatment of large great saphenous veins of diameters > 12 mm: A systematic review meta-analysis and meta-regression. Vasc Med. 2023 Oct;28(5):449-457. doi: 10.1177/1358863X231183997. Epub 2023 Jul 17.
PMID: 37458188BACKGROUNDElboushi A, Elsherbeni M, Gameel AM, et al. The 1470 radial endovenous laser ablation of the great saphenous vein larger than 12 mm: Is it a good option? A single-center expe-rience? Egyptian J Surg 2019; 38: 136-141.
BACKGROUNDDabbs EB, Mainsiouw LE, Holdstock JM, Price BA, Whiteley MS. A description of the 'smile sign' and multi-pass technique for endovenous laser ablation of large diameter great saphenous veins. Phlebology. 2018 Sep;33(8):534-539. doi: 10.1177/0268355517734480. Epub 2017 Sep 28.
PMID: 28956693BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- NETWORK
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
May 2, 2025
First Posted
May 14, 2025
Study Start
March 15, 2025
Primary Completion
September 15, 2025
Study Completion
February 15, 2026
Last Updated
May 14, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- From 15 March 2025 to 15 February 2026
The study data are available to all investigators in the chronic vein disease registry